2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1774

Chronological Analysis of Damage Accrual in Patientes with Systemic Lupus Erythematosus: Results from the Spanish Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)
Abstract Number: 2988

Cigarette Smoking Increases the Risk of Anti-Double-Stranded DNA Positive SLE Among Women in the Nurses’ Health Studies
Abstract Number: 595

Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Abstract Number: 2839

Circulating CD4+CD28null T-Cells Predict the Occurrence of New Lung Damage in Systemic Lupus Erythematosus (SLE) Patients
Abstract Number: 939

Circulating IgG4 Antibody Secreting Cells Are Better Biomarker of Disease Activity Compared to Serum IgG4 Levels in Patients with IgG4-Related Disease
Abstract Number: 3108

Citrullinated Aggrecan Peptides Are Targets of Auto-Reactive CD4+ T-Cells in Rheumatoid Arthritis
Abstract Number: 3020

Citrullination of Inhibitor of DNA Binding-1 at Specific Locations Leads to Autoantigenicity in Rheumatoid Arthritis
Abstract Number: 1999

Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug
Abstract Number: 1180

Class V Lupus Nephritis Results in Significant Numbers of End Stage Renal Disease and Death in a Population-Based Registry
Abstract Number: 891

Clinal Characterisitics and Diagnosis of Patients with Negative Temporal Artery Biopsy and without a Final Diagnosis of Giant Cell Arteritis
Abstract Number: 620

Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
Abstract Number: 1349

Clinical Analysis of Hypertrophic Pachymeningitis
Abstract Number: 347

Clinical Analysis of Tumor-Induced Osteomalacia Misdiagnosed As Spondyloarthritis: A Report of 18 Cases
Abstract Number: 627

Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
Abstract Number: 2681

Clinical and Immunological Characteristics of Primary Sjogren´s Syndrome in Men

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].